LEDUC, AB, July 19, 2021 / CNW / – PBG BioPharma Inc. (“PBG” or the “Company”), is pleased to announce that Health Canada has issued the Company with a Standard Processing License under the Cannabis Act, allowing the Company to begin manufacturing cannabis / hemp on a commercial scale immediately operations.
The Standard Processing License allows PBG to process and / or sell cannabis / hemp-derived ingredients, including extracts, concentrates and isolates to other licensed partners. It also allows the company to develop and manufacture Cannabis 2.0 products, including oils, topicals, vapes, and edibles. With its unrivaled expertise and technologies in extraction, distillation, isolation and purification, including crystallization and nano-emulsification, the company can produce innovative, purified and highly sought-after ingredients derived from hemp. / cannabis such as CBD, CBG, CBN and THC to meet various needs in the recreational and health / wellness markets for medical and adult use.
In addition, PBG has already received its cannabis testing license from Health Canada for its state-of-the-art GMP and ISO compliant research and analytical laboratories. Led by highly experienced staff, PBG Labs offers all cannabis-related laboratory testing and product development services, including testing for active ingredients, terpene profiles and impurities as well as new custom formulations. With the newly received Standard Processing License, PBG is able to provide one-stop services from ingredient extraction and product manufacturing to product release.
“This is a big step forward towards realizing our company’s overall vision,” said PBG BioPharma Founder, President and CEO, Dr. Jacqueline Shan, said of this achievement. “We are extremely excited to begin applying our proprietary innovative technologies to manufacture and market cannabis / hemp-derived health and wellness products. We can now provide innovative contract manufacturing and product development solutions to hemp / cannabis industry partners. ”
PBG also expects to receive its sales modification license shortly thereafter, which will allow the company to sell branded and / or white label consumer products to licensed cannabis retailers.
Situated in Leduc, Alberta, PBG BioPharma’s state-of-the-art 25,000 square foot licensed cannabis manufacturing, extraction and testing facility has the capacity to extract over 350,000 kg of cannabis / hemp biomass per year and to manufacture a wide range of Cannabis 2.0 products.
The facility has state-of-the-art extraction, purification, formulation and manufacturing capabilities, including proprietary crystallization technology to transform crude oils into highly purified CBD crystals and proprietary nano-emulsification technology for the products. Water soluble CBD and / or THC. The facility will provide B2B partners with a complete solution for their products by speeding up manufacturing and analysis processes. This facility is designed to meet the needs of licensed companies looking to launch Cannabis 2.0 products and places PBG in a prime position to market directly to international companies looking to create white label or branded product lines. private.
About PBG BioPharma Inc.
PBG BioPharma is a vertically integrated biopharmaceutical company focused on the research and development, testing and manufacturing of nutraceuticals and biopharmaceuticals, including science-based cannabis products. Using its proprietary GenBioChem® Triple Fingerprinting Technology platform, the company takes a pharmaceutical approach to the development, testing and manufacturing process of its products. PBG BioPharma products are rigorously tested and standardized by chemical, biological and genomic fingerprints to ensure product consistency, traceability, purity and potency from batch to batch, and meet or exceed regulatory standards. PBG BioPharma is currently conducting research and development in the areas of immunotherapy, broad spectrum antiviral therapy, neuropathic pain and the management of other neurological disorders.
SOURCE PBG BioPharma Inc.